

Appendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview

Study Name	Year	Reference	Trial duration in months	RA disease duration in years	Intervention	Comparator
ABATACEPT (n=7)						
Moreland	2002	Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. <i>Arthritis Rheum.</i> 2002 Jun;46(6):1470-9. [W1]	3	3.3	ABA	PL
Genovese	2005	Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. <i>N Engl J Med.</i> 2005 Sep 15;353(11):1114-23. [W2]	6	11.9	ABA + DMARD	DMARD + PL
Schiff	2008	Schiff MH, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. <i>Ann Rheum Dis.</i> 2008 Dec 15. [W3]	6	8.1	ABA + MTX	MTX + PL
Kremer	2003	Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfield S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. <i>N Engl J Med.</i>	6	9.2	ABA + MTX	MTX + PL

Kremer	2006	2003 Nov 13;349(20):1907-15. [W4] Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006 Jun 20;144(12):865-76. [W5]	12	8.6	ABA + MTX	MTX + PL
Weinblatt	2007	Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007 Feb;66(2):228-34. [W6]	12	12.9	ABA + ETN	ETN + PL
Weinblatt (ASSURE)	2006	Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006 Sep;54(9):2807-16.[W7]	12	9.7	ABA + DMARD(biologic + non-biologic) + PL	DMARD(biologic + non-biologic) + PL
ADALIMUMAB (n=8)						
Bejarano	2008	Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008 Oct 15;59(10):1467-74. [W8]	13	0.9	ADA + MTX	MTX + PL
Breedveld	2006	Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER	24	0.7	ADA + MTX	MTX + PL

Appendix to: Singh JA, Christensen R, Wells, GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. *CMAJ* 2009. DOI 10.1503/cmaj.091391.
Copyright © 2009, Canadian Medical Association.

			study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. <i>Arthritis Rheum.</i> 2006 Jan;54(1):26-37. [W9]			
Furst	2003	Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). <i>J Rheumatol.</i> 2003 Dec;30(12):2563-71. [W10]	6	10.4	ADA + DMARD	DMARD + PL
Keystone	2004	Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. <i>Arthritis Rheum.</i> 2004 May;50(5):1400-11. [W11]	12	11.0	ADA + MTX	MTX + PL
Kim	2007	Kim H, Lee S, Song Y, Yoo D, Koh EM, Yoo B, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean	6	6.8	ADA + MTX	MTX + PL

		rheumatoid arthritis patients treated with methotrexate. APLAR Journal of Rheumatology. 2007;10:9-16. [W12]				
Miyasaka	2008	Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18(3):252-62. [W13]	6	9.8	ADA	PL
Van de Putte	2004	van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004 May;63(5):508-16. [W14]	6	11.1	ADA	PL
Weinblatt	2003	Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan;48(1):35-45. [W15]	6	11.7	ADA + MTX	MTX + PL
ANAKINRA						
Bresnihan	1998	Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998 Dec;41(12):2196-204.b [W16]	6	4.1	ANA	PL
Fleischman	2003	Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human	6	10.3	ANA + DMARD	PL + DMARD

Appendix to: Singh JA, Christensen R, Wells, GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. *CMAJ* 2009. DOI 10.1503/cmaj.091391.
 Copyright © 2009, Canadian Medical Association.

		interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. <i>Arthritis Rheum.</i> 2003 Apr;48(4):927-34. [W17]				
Cohen	2002	Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis Rheum.</i> 2002 Mar;46(3):614-24. [W18]	6	7.8	ANA + MTX	MTX + PL
Cohen	2004	Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Sherry WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. <i>Ann Rheum Dis.</i> 2004 Sep;63(9):1062-8. [W19]	6	10.5	ANA + MTX	MTX + PL
Genovese	2004	Genovese MC, Cohen S, Moreland L, Liim D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. <i>Arthritis Rheum.</i> 2004 May;50(5):1412-9. [W20]	6	10.2	ANA + ETN +MTX	ETN + MTX + PL
ETANERCEPT						
Moreland	1999	Moreland LW, Schiff MH, Baumgartner	6	11.5	ETA	PL

		SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478-86. [W21]				
Weinblatt	1999	Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253-9. [W22]	6	13.0	ETA + MTX	MTX + PL
Emery (COMET)	2008	Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008 Aug 2;372(9636):375-82. [W23]	12	0.9	ETA + MTX	MTX + PL
Klareskog (TEMPO)	2004	Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675-81. [W24]	12	6.8	ETA + MTX	MTX + PL
INFliximab						
Maini	1998	Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody	6	9.9	INF + MTX	MTX + PL

			combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552-63. [W25]				
St. Clair (ASPIRE)	2004	St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al.	Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004 Nov;50(11):3432-43. [W26]	12	0.8	INF + MTX	MTX + PL
Lipsky (ATTRACT)	2000	Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al.	Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594-602. [W27]	12	10.5	INF + MTX	MTX + PL
Quinn	2005	Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al.	Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 Jan;52(1):27-35. [W28]	12	0.7	INF + MTX	MTX + PL
RITUXIMAB							
Edwards	2004	Edwards JC, Szczerpani L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al.	Efficacy of B-cell-targeted therapy with rituximab in patients with	6	11.5	RIT + MTX	MTX + PL

		rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572-81. [W29]				
Emery (DANCER)	2006	Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006 May;54(5):1390-400. [W30]	6	10.1	RIT + MTX	MTX + PL
Cohen (REFLEX)	2006	Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006 Sep;54(9):2793-806. [W31]	6	11.9	RIT + MTX	MTX + PL